9M 2023 Financial Overview
9M 2023: APPENDIX
Solid revenue and Adjusted EBITDA
growth to continue mid-term
Revenue performance (DKKbn)
2019
2020
2021
2022
2023E1
Adj. EBITDA margin (%)
Mid-single
digit CAGR
•
Mid-term
aspiration
-30-32%
56
1) Mid-point. AADAD: agitation associated with dementia due to Alzheimer's disease. 2M RTU: two-monthly ready-to-use
Expected organic development
towards mid-term aspiration
(3-4 years)
•
Continued double-digit growth for strategic
brands in aggregate
Continued erosion of mature brands sales
Amortization of product rights expected
DKK 1.4bn annually
Launch investments for Vyepti, Rexulti AADAD
and aripiprazole 2M RTU to drive mid-term
growth
R&D costs expected to remain broadly stable
supporting the transformation of R&DView entire presentation